| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Sep'17 |
|---|---|---|---|---|---|---|---|---|---|
Revenue: | |||||||||
Precision oncology testing | |||||||||
60,246 | 57,414 | 52,147 | 42,064 | 28,837 | 28,096 | 18,298 | 17,822 | 14,191 | 10,253 |
Development services | |||||||||
7,264 | 5,483 | 8,701 | 11,911 | 7,818 | 4,777 | 3,394 | 1,560 | 2,501 | 879 |
Revenues | |||||||||
67,510 | 62,897 | 60,848 | 53,975 | 36,655 | 32,873 | 21,692 | 19,382 | 16,692 | 11,132 |
Costs and operating expenses: | |||||||||
Cost of precision oncology testing | |||||||||
18,191 | 20,004 | 16,578 | 14,650 | 11,023 | 12,624 | 9,671 | 9,506 | 8,045 | 7,603 |
Cost of development services | |||||||||
2,315 | 1,834 | 1,936 | 2,183 | 2,512 | 1,323 | 380 | 453 | 1,208 | 1,058 |
Research and development expense | |||||||||
37,016 | 25,875 | 24,569 | 19,532 | 16,316 | 16,652 | 14,253 | 11,554 | 8,255 | 7,246 |
Sales and marketing expense | |||||||||
25,115 | 22,287 | 18,802 | 19,439 | 17,807 | 17,114 | 13,464 | 11,575 | 11,312 | 7,808 |
General and administrative expense | |||||||||
19,785 | 18,859 | 16,440 | 13,439 | 12,661 | 12,547 | 8,129 | 8,997 | 6,519 | 16,095 |
Total costs and operating expenses | |||||||||
102,422 | 88,859 | 78,325 | 69,243 | 60,319 | 60,260 | 45,897 | 42,085 | 35,339 | 39,810 |
Loss from operations | |||||||||
-34,912 | -25,962 | -17,477 | -15,268 | -23,664 | -27,387 | -24,205 | -22,703 | -18,647 | -28,678 |
Interest income | |||||||||
3,318 | 3,871 | 4,286 | 3,099 | 2,485 | 2,334 | 958 | 989 | 985 | 657 |
Interest expense | |||||||||
12 | 321 | 280 | 287 | 293 | 299 | 304 | 317 | 331 | 303 |
Gain (Loss) on Extinguishment of Debt | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Other (expense) income, net | |||||||||
-209 | -187 | 179 | -51 | 147 | 115 | 43 | 395 | 4,149 | -266 |
Loss before provision for income taxes | |||||||||
-31,815 | -22,599 | -13,292 | -12,507 | -21,325 | -25,237 | -23,508 | -21,636 | -13,844 | -28,590 |
Provision for income taxes | |||||||||
14 | -489 | -202 | -1,207 | 26 | 35 | 0 | 3 | 0 | 0 |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | |||||||||
-31,829 | -22,110 | -13,090 | -11,300 | -21,351 | -25,272 | -23,508 | -21,639 | -13,844 | -28,590 |
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest | |||||||||
-4,100 | 3,100 | -300 | 300 | 4,700 | -150 | 950 | 0 | 0 | 0 |
Net loss attributable to Guardant Health, Inc. | |||||||||
- | - | - | - | - | - | - | - | - | -28,590 |
Net Income (Loss) Available to Common Stockholders, Basic | |||||||||
-27,729 | -25,210 | -12,790 | -11,600 | -26,051 | -25,122 | -24,458 | -21,639 | -13,844 | -33,306 |
Net loss per share attributable to common stockholders, basic and diluted (in usd per share) | |||||||||
-0.29 | -0.27 | -0.14 | -0.13 | -0.30 | 2.05 | -1.94 | -1.75 | -1.16 | -2.76 |
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares) | |||||||||
94,382 | 94,114 | 93,303 | 89,036 | 85,935 | 84,722 | 12,582 | 12,388 | 11,920 | 12,073 |
Series A Convertible Preferred Stock | |||||||||
Deemed dividend related to repurchase of convertible preferred stock | |||||||||
- | - | - | - | - | - | - | - | - | 4,716 |
Series D Convertible Preferred Stock | |||||||||
Deemed dividend related to repurchase of convertible preferred stock | |||||||||
- | - | - | - | - | - | - | - | - | 0 |